Home › Companies › OVID

Ovid Therapeutics

Market cap $419M 188.7M shares (10-Q, Nov 4, 2026) × $2.22 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. OV4041 IND filing2H 2026OV4041 IND filing, 2H 2026, notable
  2. OV4071 Ph1 start2H 2026OV4071 Ph1 start, 2H 2026, routine
  3. OV329 readoutnear year end 2026OV329 readout, near year end 2026, notable
  4. OV329 topline2H 2027OV329 topline, 2H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

KCC2 Direct Activator Library · AstraZeneca

Portfolio of more than 100 small molecules that directly activate the KCC2 potassium-chloride cotransporter, exclusively expressed in the CNS. Programs emerging from the library are being evaluated for psychosis, schizophrenia, mood disorders, and seizures, including neurodegenerative and neurodevelopmental conditions. In-licensed from AstraZeneca in 2021.

Targets: KCC2

Gensaic Intracellular Delivery Platform · Gensaic

Proprietary tissue-selective intracellular delivery platform for genetic medicines targeting neurological indications. Collaboration with Gensaic to potentially develop up to three genetic medicines for neurological indications of interest to Ovid.

Gensaic PDP Platform · Gensaic

Gensaic's proprietary phage-derived particle (PDP) platform for rare central nervous system (CNS) disorder targets; Ovid holds an option to obtain an exclusive license for identified lead PDP products.

Discontinued (1)

Capital (as filed)

Cash
$13.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$123M Sep 30, 2026
Long-term investments
$24.8M Sep 30, 2026
Operating cash flow
−$15.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$161M cash, runway into 2029 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Ovid Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Ovid Therapeutics (OVID): Scientific Deep Dive for OV329 and Pipeline Products Post-balance-sheet-repair Ovid offers asymmetric risk/reward on validated GABA-AT and novel KCC2 mechanisms, with cash runway now extended to 2H 2028 removing near-term dilution risk.
  2. Speculative buy speculative UPDATE: Ovid Therapeutics (OVID) - $60M Double Down and the Death of the Dilution Gap A second $60M PIPE from the same top-tier syndicate buries the dilution gap and funds Ovid through its 2027 Phase 2a readouts, though the science remains highly speculative.
  3. Speculative buy speculative UPDATE: Ovid Therapeutics (OVID) - The Warrants Print, the CEO Changes, the Thesis Tightens With ~$175M pro-forma cash funding every catalyst and execution risk now the dominant concern under new CEO Meg Alexander, the speculative buy is maintained while watching for her first operational delivery.
  4. Speculative buy speculative UPDATE: Ovid Therapeutics (OVID) - The KCC2 Switch Gets Flipped (in a Human) OV4071 first-in-human dosing, clean OV329 9mg escalation, and two new pediatric indications expand the catalyst surface while the mid-2027 Phase 2a FOS topline remains the binary event.
  5. Speculative buy speculative UPDATE: Ovid Therapeutics (OVID) - A New CBO Who Just Sold a Company to Neurocrine Hiring the CBO who ran Soleno's sale to Neurocrine operationalizes the M&A optionality thesis while the science and cash position remain unchanged ahead of late-2026 data catalysts.
  6. Speculative buy speculative UPDATE: Ovid Therapeutics (OVID) - The Free Look Just Got Scheduled The PPR photosensitivity readout scheduled for year-end 2026 compresses the catalyst clock by nine months, the Phase 2 was upgraded to registrational-grade design, and soticlestat returned as free optionality.
  7. Speculative buy speculative UPDATE: Ovid Therapeutics (OVID) - The Free Look Slips a Quarter PPR readout slips one quarter to Q1 2027 alongside OV4071 Phase 1 and ketamine challenge data, concentrating three binary readouts in one quarter while burn climbs and a fresh $75M ATM adds dilution watch risk.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

21 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)